Alleviating Carbohydrate Counting Using Weekly Subcutaneous Semaglutide Injections in People With Type 1 Diabetes on Closed-Loop Insulin Therapy: a 2x4 Factorial Randomized Placebo-Controlled Trial
Latest Information Update: 23 Dec 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SEMA SMA
- 18 Dec 2024 Planned End Date changed from 1 Jul 2026 to 1 Jan 2027.
- 18 Dec 2024 Planned primary completion date changed from 1 Jul 2026 to 1 Jan 2027.
- 18 Dec 2024 Status changed from not yet recruiting to recruiting.